Effective October 16, 2017, the National Cancer Institute (NCI), through the NCI Technology Transfer Center (TTC), offers a term-limited, exclusive Start-Up Evaluation Option License to start-up companies developing early-stage vaccine, therapeutic, device, and certain diagnostic technologies. The previous Start-up Program offered by the NIH Office of Technology Transfer will apply if companies submitted a license application for a start-up agreement on or before October 15, 2017. Please contact the appropriate NCI Technology Transfer Manager for further clarification.
Start-Up Evaluation Option Agreements are available to companies that meet the following criteria:
1) less than 5 years old;
2) have less than $5 million in capital raised; and
3) have fewer than 50 employees.
Participating NIH Institutes and Centers
The Start-Up Evaluation Option License encompasses select intramural inventions from NCI and the nine NIH Institutes and Centers served by the TTC:
- NIH Clinical Center;
- NIH Center for Information Technology;
- National Center for Complimentary and Integrative Health;
- National Eye Institute;
- National Institute on Aging;
- The Eunice Kennedy Shriver National Institute for Child Health and Human Development;
- National Institute for Drug Abuse;
- National Library of Medicine; and
- National Institute on Minority Health and Health Disparities.
The NCI Start-Up Evaluation Option License provides short-term exclusivity to certain NIH technologies while companies evaluate a technology or raise funding for future development. Companies can convert to a full NIH Exclusive Patent License at the end of the option period if the company plans to continue commercial development of the technology.
Companies must license at least one United States patent and commit to developing a product or service for the US market. Companies may license patents filed in other countries if the company commits to bringing products to markets in those countries as well.
Features of the NCI Start-Up Evaluation Option License include:
- 24-month option period;
- $5,000 execution royalty within 60 days of the effective date;
- $5,000 patent royalty due on the one year anniversary of the effective date;
- Eligible technologies are claimed in patent applications or patents that are at least four years old from the earliest priority application filing date;
- NCI and NCI client Institutes pay on-going patent expenses for licensed patent rights during the option period; and
- Option to convert to an Exclusive Patent License, not automatic, but conditioned upon a) meeting the milestones in the Option Agreement and b) a revised Commercial Evaluation Plan that supports commercial advancement of the technology.
The process to obtain a Start-Up Evaluation Option License is:
- Identify a technology of interest from this list of NIH inventions;
- Companies submit a License Application for their chosen technology, including an initial, but detailed, Commercial Evaluation Plan to the TTC Technology Transfer Manager;
- Based on the Commercial Evaluation Plan submitted to the TTC, companies negotiate a license Field of Use with the NCI Technology Transfer Manager;
- NCI will advertise a "Notice of Intent to Grant an Exclusive License" in the Federal Register (FRN) with a notice period of 15 days;
- The company and the Technology Transfer Manager negotiate and finalize the Start-Up Evaluation Option License if no objections to the FRN are received.
The application for the Start-Up Evaluation Option License is available on this web site. Guidance for completing the license application can be obtained by reviewing the Guidance Document or by contacting the NCI TTC. Please note this Guidance Document is ONLY to assist in completing the license application.
For any questions regarding this program, please contact Mr. Richard Rodriguez, Associate Director, NCI Technology Transfer Center by email or by telephone 240-276-6661.